Antonella Santucci
Overview
Explore the profile of Antonella Santucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
1037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pasticci M, Moretti A, Stagni G, Ravasio V, Soavi L, Raglio A, et al.
Ann Clin Microbiol Antimicrob
. 2011 Jun;
10:26.
PMID: 21658248
Background: There is no clear relationship between in vitro bactericidal activity tests and clinical outcome. We studied bactericidal activity of oxacillin, vancomycin and teicoplanin against Staphylococcus aureus isolates in patients...
2.
La Starza R, Matteucci C, Gorello P, Brandimarte L, Pierini V, Crescenzi B, et al.
PLoS One
. 2010 Sep;
5(9):e12855.
PMID: 20877721
Background: NPM1 gene at chromosome 5q35 is involved in recurrent translocations in leukemia and lymphoma. It also undergoes mutations in 60% of adult acute myeloid leukemia (AML) cases with normal...
3.
Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, et al.
Blood
. 2010 Mar;
115(18):3776-86.
PMID: 20203266
NPM1-mutated acute myeloid leukemia (AML) is a provisional entity in the 2008 World Health Organization (WHO) classification of myeloid neoplasms. The significance of multilineage dysplasia (MLD) in NPM1-mutated AML is...
4.
Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, et al.
Blood
. 2009 May;
114(14):3024-32.
PMID: 19429869
Acute myeloid leukemia (AML) with mutated NPM1 usually carries normal karyotype (NK), but it may harbor chromosomal aberrations whose significance remains unclear. We addressed this question in 631 AML patients...
5.
Aversa F, Tabilio A, Velardi A, Terenzi A, Falzetti F, Carotti A, et al.
Curr Stem Cell Res Ther
. 2008 Jan;
2(1):105-12.
PMID: 18220895
Much progress has been made in the clinical, biological and technical aspects of the T-cell-depleted full-haplotype mismatched transplants for acute leukemia. Our experience demonstrates that infusing a megadose of extensively...
6.
Di Bella I, Da Col U, Ciampichini R, Affronti A, Santucci A, Fabbri M, et al.
G Ital Cardiol (Rome)
. 2007 Jul;
8(5):306-10.
PMID: 17650689
Background: The aim of this study was to cross validate a new scoring system, based on preoperative risk factors, in predicting the risk of postoperative dialysis after cardiac surgery and...
7.
Di Bella I, Da Col U, Sindaco F, Pasquino S, Affronti A, Santucci A, et al.
Ital Heart J Suppl
. 2005 Jul;
6(6):365-8.
PMID: 16013428
Background: One of the most utilized systems for risk stratification in cardiac surgery is the EuroSCORE. It considers some risk factors that should influence the surgical risk. The aim of...
8.
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al.
J Clin Oncol
. 2005 Mar;
23(15):3447-54.
PMID: 15753458
Purpose: Establishment of hematopoietic stem-cell (HSC) transplantation from mismatched relatives is feasible for patients with acute leukemia. As our original method of graft processing was unsuitable for large-scale clinical studies,...
9.
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al.
N Engl J Med
. 2005 Jan;
352(3):254-66.
PMID: 15659725
Background: Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein. Methods: We...
10.
Tabilio A, Falzetti F, Zei T, De Ioanni M, Bonifacio E, Battelli F, et al.
Blood Cells Mol Dis
. 2004 Nov;
33(3):274-80.
PMID: 15528144
Haploidentical stem cell transplantation has became a clinical reality in the last 10 years as it provides the chance of transplant for about 50% of patients with hematological malignancies who...